Please login to the form below
Ranbaxy
This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.
Nearly half of all clinical trials not published
Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35
Latest news
-
Lundbeck challenge to EC pay-for-delay ruling fails
The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.
-
India denies Vertex patent on cystic fibrosis drug Orkambi
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
-
Heart drug sales continue downward spiral
The Swiss firm has managed to delay some generic forms of its drug onto the market until last year, when Ranbaxy was granted approval to sell its copycat form of valsartan.
-
Takeda to pay $2.4bn to settle Actos cancer suits
Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but now also faces generic competition from India's Ranbaxy Laboratories.
-
Teva slapped with $512m fine on pay-for-delay deal
Ranbaxy Laboratories. ... Mylan and Ranbaxy, which are also defendants in the case, are not part of the settlement.
More from news
Approximately 7 fully matching, plus 107 partially matching documents found.
Latest Intelligence
-
Pharma deals in April 2015
The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy
-
Allergan and taking a specialised approach
But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and
-
Pharma deals during April 2014
The total cost of the all-stock acquisition is $4.0bn (an 18% premium), $3.2bn in stock and nearly $800m of Ranbaxy debt. ... Eclipsing all else will be restoring FDA confidence. To this end immediate remedial action will involve management restructuring
-
Deal Watch table for April 2014
Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.
-
Positive prospects for pharma in Latin America
Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Clinical Trials Market : Dynamics, Segments, Size and Demand, 2015 - 2025
Some of the market leaders contributing to the global clinical trials market include Eli Lilly and Company, Novo Nordisk A/S, Ranbaxy Laboratories, Ltd., Sanofi Aventis A.S.
-
Competition from within
Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘ BRIC’ markets (Brazil,
-
Exploring MINT: Part 3 - Nigeria
At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.
-
Exploring MINT: Part 3 - Nigeria
At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Medical/ Scientific Director
-
Salary TBC
- Director, Market Access / HEOR - North-West
-
Negotiable
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
-
Account Director
-
Excellent benefits
-
Senior Account Manager
-
Negotiable
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Senior Medical Writer
-
Competitive Salary
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Senior Medical Writer
-
Great salary and benefits
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
-
Associate Medical Director
-
Highly Competitive
- Senior Account Director development role to Business Director, H...
-
Excellent package
Subscribe to our email news alerts
- Bioprocessing Analytics Equipment Market is anticipated to register a CAGR of 4.5% over the forecast period 2028
- Behavioural Health Market is expected to expand at 3.4% CAGR over the forecast period 2018-2028.
- Prurigo Nodularis Treatment Market is poised to expand at 3.4% CAGR over the forecast period of 2018–2028
- Biologic Excipients Market is projected to register a CAGR of 3.6% over the forecast period 2018-2028
- Bone Screw System Market to reach a market value of US$ 1,963 Mn in 2028
- Enzyme Replacement Therapy Market is expected to exceed US$ 13,776.2 Mn by 2028 end
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
